Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.39 |
| ▸ | CACNA1I | Q9P0X4 | 5/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4271194 | 0.80 | KCNH2 (0.48) | KDM4EPKMSMYD3KCNH2CACNA1I | |
| SCHEMBL14769940 | 0.78 | HTR4 (0.52) | SMYD3KCNH2CACNA1IDHODHMCHR1 | |
| SCHEMBL31520356 | 0.77 | NPC1L1 (0.46) | KDM4EPKMSMYD3ACACBACACA | |
| SCHEMBL8370950 | 0.74 | SMYD3 (0.53) | SMYD3KCNH2CACNA1IDHODHMCHR1 | |
| SCHEMBL16459248 | 0.72 | SMYD3 (0.49) | SMYD3KCNH2CACNA1IDHODHMCHR1 | |
| SCHEMBL19701715 | 0.66 | SMYD3 (0.58) | SMYD3DHODH | |
| SCHEMBL3645227 | 0.65 | GPR119 (0.45) | KDM4EPKMMCHR1 | |
| SCHEMBL6879845 | 0.65 | MCHR1 (0.72) | SMYD3KCNH2MCHR1 | |
| SCHEMBL6879851 | 0.65 | MCHR1 (0.72) | SMYD3KCNH2MCHR1 | |
| SCHEMBL20615646 | 0.64 | KDM4E (0.79) | KDM4EPKMKCNH2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377968-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2013-02-19 | — | — | US | disclosed |
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298883-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | KDM4E 4392/4885PKM 4034/4885SMYD3 3801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.